| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
|
N Engl J Med
|
2013
|
18.08
|
|
2
|
Pembrolizumab for the treatment of non-small-cell lung cancer.
|
N Engl J Med
|
2015
|
10.12
|
|
3
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2006
|
6.77
|
|
4
|
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
|
J Clin Oncol
|
2011
|
4.53
|
|
5
|
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
|
J Clin Oncol
|
2007
|
3.37
|
|
6
|
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
3.36
|
|
7
|
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
|
J Clin Oncol
|
2008
|
2.65
|
|
8
|
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
|
J Clin Oncol
|
2009
|
2.63
|
|
9
|
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
|
J Clin Oncol
|
2008
|
2.35
|
|
10
|
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
|
J Clin Oncol
|
2006
|
2.35
|
|
11
|
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
2.30
|
|
12
|
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
|
J Clin Oncol
|
2012
|
2.04
|
|
13
|
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.96
|
|
14
|
Raf: a strategic target for therapeutic development against cancer.
|
J Clin Oncol
|
2005
|
1.63
|
|
15
|
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
|
Cancer
|
2007
|
1.52
|
|
16
|
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2005
|
1.23
|
|
17
|
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
|
J Clin Oncol
|
2003
|
1.21
|
|
18
|
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
|
J Hematol Oncol
|
2014
|
1.20
|
|
19
|
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
1.19
|
|
20
|
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2008
|
1.14
|
|
21
|
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
|
Cancer Chemother Pharmacol
|
2006
|
1.02
|
|
22
|
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
|
Clin Cancer Res
|
2004
|
1.01
|
|
23
|
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
|
Clin Cancer Res
|
2007
|
1.01
|
|
24
|
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
|
Clin Cancer Res
|
2004
|
1.00
|
|
25
|
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
1.00
|
|
26
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
|
Clin Cancer Res
|
2014
|
0.95
|
|
27
|
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
|
J Clin Oncol
|
2003
|
0.92
|
|
28
|
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
|
Clin Cancer Res
|
2011
|
0.91
|
|
29
|
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
|
J Clin Oncol
|
2006
|
0.91
|
|
30
|
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.91
|
|
31
|
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
|
Clin Cancer Res
|
2004
|
0.89
|
|
32
|
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
|
Cancer Chemother Pharmacol
|
2006
|
0.87
|
|
33
|
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
|
Cancer Chemother Pharmacol
|
2014
|
0.87
|
|
34
|
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.84
|
|
35
|
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
0.84
|
|
36
|
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2004
|
0.84
|
|
37
|
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
|
Clin Cancer Res
|
2003
|
0.83
|
|
38
|
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2008
|
0.83
|
|
39
|
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
|
J Clin Oncol
|
2002
|
0.81
|
|
40
|
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.81
|
|
41
|
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
|
Anticancer Res
|
2014
|
0.81
|
|
42
|
Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
|
Anticancer Res
|
2005
|
0.80
|
|
43
|
Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
|
J Clin Pharmacol
|
2013
|
0.78
|
|
44
|
Regulation of c-Raf-1: therapeutic implications.
|
Clin Adv Hematol Oncol
|
2003
|
0.77
|
|
45
|
Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer.
|
J Ovarian Res
|
2013
|
0.75
|
|
46
|
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|
|
47
|
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
|
Invest New Drugs
|
2004
|
0.75
|
|
48
|
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
|
Hematol Oncol Clin North Am
|
2002
|
0.75
|
|
49
|
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.
|
J Clin Pharmacol
|
2014
|
0.75
|
|
50
|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
|
Cancer Chemother Pharmacol
|
2009
|
0.75
|